Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on VIR.
Vir Biotechnology Inc. (VIR)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 5,666,821 | $57,744,906 | +191% | 0.06% |
| 2. | ADAR1 Capital Management Daniel Schneeberger | 2,456,677 | $25,033,539 | -11% | 1.15% |
| 3. | Boxer Capital Aaron Davis And Christopher Fuglesang | 1,866,000 | $19,014,540 | 1.43% | |
| 4. | Hudson Bay Capital Management Sander Gerber | 1,364,000 | $13,899,160 | -8% | 0.04% |
| 5. | GordonMD Global Investments Craig Gordon | 1,353,552 | $13,792,695 | -11% | 6.67% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.73 | 2,500 | $56,815.50 | 10,000 | 2023-03-01 | Filing | |
| $24.96 | 2,500 | $62,395.50 | 7,500 | 2023-01-05 | Filing | |
| $25.25 | 2,500 | $63,136.25 | 5,000 | 2023-01-04 | Filing | |
| $25.60 | 2,500 | $63,992.50 | 2,500 | 2023-01-03 | Filing | |
| $43.39 | 12 | $499.85 | 12 | 2021-11-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.45 | 3,200 | $30,240.00 | 21,216 | 2026-06-01 | Filing | |
| $9.45 | 379 | $3,581.55 | 61,902 | 2026-06-01 | Filing | |
| $10.05 | 22,000 | $221,025.20 | 1,078,391 | 2026-05-01 | Filing | |
| $9.16 | 72,559 | $664,350.20 | 948,145 | 2026-04-06 | Filing | |
| $9.07 | 22,000 | $199,617.00 | 1,100,391 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,678,283 | $210,711,705 | 0% | |
| 2. | 12,694,163 | $129,353,521 | 11.76% | |
| 3. | 11,495,215 | $117,136,241 | 0.01% | |
| 4. | 10,948,093 | $111,561,068 | 1.46% | |
| 5. | 9,964,151 | $101,534,699 | 0% |
News See All
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2026 Earnings Call Transcript May 6, 2026Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, expectations were $-0.01.
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR.
10 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds
In this article, we will look at the 10 Best Small Cap Biotech Stocks to Buy According to Hedge Funds.
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the best low priced biotech stocks to invest in. On April 13, Vir Biotechnology, Inc.
8 Must-Buy Small Cap Stocks to Buy
In this article, we will look at the 8 Must-Buy Small Cap Stocks to Buy. After many years of large capitalization companies dominating the US equities market, time is ripe for rotation.
8 Best Low Priced Biotech Stocks to Invest In
In this article, we will look at the 8 Best Low Priced Biotech Stocks to Invest In.
Vir Biotechnology (VIR) Leading with Its BiTEs Therapy
Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2025 Earnings Call Transcript
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2025 Earnings Call Transcript November 5, 2025Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is $-1.17427 EPS, expectations were $-0.7.
Hedge Fund Resource Center